Literature DB >> 28941939

Complete functional characterization of disease-associated genetic variants in the complement factor H gene.

Héctor Martín Merinero1, Sheila Pinto García1, Jesús García-Fernández1, Emilia Arjona1, Agustín Tortajada2, Santiago Rodríguez de Córdoba3.   

Abstract

Genetic analyses in atypical hemolytic uremic syndrome (aHUS) and C3-glomerulopathy (C3G) patients have provided an excellent understanding of the genetic component of the disease and informed genotype-phenotype correlations supporting an individualized approach to patient management and treatment. In this context, a correct categorization of the disease-associated gene variants is critical to avoid detrimental consequences for patients and their relatives. Here we describe a comprehensive procedure to measure levels and functional activity of complement regulator factor H (FH) encoded by CFH, the commonest genetic factor associated with aHUS and C3G, and present the results of the analysis of 28 uncharacterized, disease-associated, FH variants. Sixteen variants were not expressed in plasma and eight had significantly reduced functional activities that impact on complement regulation. In total, 24 of 28 CFH variants were unambiguously categorized as pathogenic and the nature of the pathogenicity fully documented for each. The data also reinforce the genotype-phenotype correlations that associate specific FH functional alterations with either aHUS or C3G and illustrate important drawbacks of the prediction algorithms dealing with variants located in FH functional regions. We also report that the novel aHUS-associated M823T variant is functionally impaired. This was unexpected and uncovered the important contribution of regions outside the N-terminal and C-terminal functional domains to FH regulatory activities on surfaces. Thus, our work significantly advances knowledge towards a complete functional understanding of the CFH genetic variability and highlights the importance of functional analysis of the disease-associated CFH variants.
Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C3 glomerulopathy; complement; hemolytic uremic syndrome

Mesh:

Substances:

Year:  2017        PMID: 28941939     DOI: 10.1016/j.kint.2017.07.015

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  20 in total

1.  Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera.

Authors:  Richard B Pouw; Mieke C Brouwer; Marlon de Gast; Anna E van Beek; Lambertus P van den Heuvel; Christoph Q Schmidt; Arie van der Ende; Pilar Sánchez-Corral; Taco W Kuijpers; Diana Wouters
Journal:  Blood Adv       Date:  2019-02-26

Review 2.  CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Peter F Zipfel; Thorsten Wiech; Emma D Stea; Christine Skerka
Journal:  J Am Soc Nephrol       Date:  2020-01-24       Impact factor: 10.121

Review 3.  Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2021-05-05       Impact factor: 28.314

4.  Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome.

Authors:  Fengxiao Bu; Yuzhou Zhang; Kai Wang; Nicolo Ghiringhelli Borsa; Michael B Jones; Amanda O Taylor; Erika Takanami; Nicole C Meyer; Kathy Frees; Christie P Thomas; Carla Nester; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2018-10-30       Impact factor: 10.121

5.  Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Amy J Osborne; Matteo Breno; Nicolo Ghiringhelli Borsa; Fengxiao Bu; Véronique Frémeaux-Bacchi; Daniel P Gale; Lambertus P van den Heuvel; David Kavanagh; Marina Noris; Sheila Pinto; Pavithra M Rallapalli; Giuseppe Remuzzi; Santiago Rodríguez de Cordoba; Angela Ruiz; Richard J H Smith; Paula Vieira-Martins; Elena Volokhina; Valerie Wilson; Timothy H J Goodship; Stephen J Perkins
Journal:  J Immunol       Date:  2018-03-02       Impact factor: 5.422

6.  Systemic complement levels in patients with age-related macular degeneration carrying rare or low-frequency variants in the CFH gene.

Authors:  Sarah de Jong; Anita de Breuk; Elena B Volokhina; Bjorn Bakker; Alejandro Garanto; Sascha Fauser; Suresh Katti; Carel B Hoyng; Yara T E Lechanteur; Lambert P van den Heuvel; Anneke I den Hollander
Journal:  Hum Mol Genet       Date:  2022-02-03       Impact factor: 6.150

7.  A single-nucleus RNA-sequencing pipeline to decipher the molecular anatomy and pathophysiology of human kidneys.

Authors:  Blue B Lake; Song Chen; Masato Hoshi; Nongluk Plongthongkum; Diane Salamon; Amanda Knoten; Anitha Vijayan; Ramakrishna Venkatesh; Eric H Kim; Derek Gao; Joseph Gaut; Kun Zhang; Sanjay Jain
Journal:  Nat Commun       Date:  2019-06-27       Impact factor: 14.919

Review 8.  Complement Inhibitors in Clinical Trials for Glomerular Diseases.

Authors:  Peter F Zipfel; Thorsten Wiech; Ramona Rudnick; Sara Afonso; Fermin Person; Christine Skerka
Journal:  Front Immunol       Date:  2019-09-27       Impact factor: 7.561

9.  Clinical and Genetic Spectrum of a Large Cohort With Total and Sub-total Complement Deficiencies.

Authors:  Carine El Sissy; Jérémie Rosain; Paula Vieira-Martins; Pauline Bordereau; Aurélia Gruber; Magali Devriese; Loïc de Pontual; Muhamed-Kheir Taha; Claire Fieschi; Capucine Picard; Véronique Frémeaux-Bacchi
Journal:  Front Immunol       Date:  2019-08-08       Impact factor: 7.561

10.  Murine Factor H Co-Produced in Yeast With Protein Disulfide Isomerase Ameliorated C3 Dysregulation in Factor H-Deficient Mice.

Authors:  Heather Kerr; Andrew P Herbert; Elisavet Makou; Dariusz Abramczyk; Talat H Malik; Hannah Lomax-Browne; Yi Yang; Isabel Y Pappworth; Harriet Denton; Anna Richards; Kevin J Marchbank; Matthew C Pickering; Paul N Barlow
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.